Patents by Inventor Timothy Andrew Woods

Timothy Andrew Woods has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESS FOR MAKING CRYSTALLINE 2-(3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-1-(CYCLOPROPYLSULFONYL)AZETIDIN-3-YL)ACETONITRILE
    Publication number: 20230056365
    Abstract: The present disclosure provides crystalline forms of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile, pharmaceutical compositions comprising the crystalline forms, methods of using the crystalline forms, and processes for making the crystalline forms.
    Type: Application
    Filed: June 2, 2022
    Publication date: February 23, 2023
    Inventors: Jingdan HU, Timothy Andrew WOODS
  • Process for making crystalline 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile
    Patent number: 11548895
    Abstract: The present disclosure provides crystalline forms of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile, pharmaceutical compositions comprising the crystalline forms, methods of using the crystalline forms, and processes for making the crystalline forms.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: January 10, 2023
    Assignee: Elanco US Inc.
    Inventors: Jingdan Hu, Timothy Andrew Woods
  • JAK INHIBITORS
    Publication number: 20200339585
    Abstract: The present disclosure provides crystalline forms of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile, pharmaceutical compositions comprising the crystalline forms, methods of using the crystalline forms, and processes for making the crystalline forms.
    Type: Application
    Filed: April 22, 2020
    Publication date: October 29, 2020
    Inventors: Jingdan Hu, Timothy Andrew Woods
  • Pyrazolylaminobenzimidazole derivatives as JAK inhibitors
    Patent number: 10323019
    Abstract: The present invention provides compounds of the formula below (I?): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: June 18, 2019
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Joshua Ryan Clayton, David Andrew Coates, Daniel Jon Sall, Timothy Andrew Woods
  • PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20190177300
    Abstract: The present invention provides compounds of the formula below (I?): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
    Type: Application
    Filed: February 12, 2019
    Publication date: June 13, 2019
    Inventors: Jolie Anne Bastian, Joshua Ryan Clayton, David Andrew Coates, Daniel Jon Sall, Timothy Andrew Woods
  • PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20180325873
    Abstract: The present invention provides compounds of the formula below (I?): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.
    Type: Application
    Filed: July 10, 2017
    Publication date: November 15, 2018
    Inventors: Jolie Anne Bastian, Joshua Ryan Clayton, David Andrew Coates, Daniel Jon Sall, Timothy Andrew Woods
  • Novel Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta, Gamma-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)carbonyl]-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1)
    Publication number: 20180009748
    Abstract: Novel forms of [R-(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptatonic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX, characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.
    Type: Application
    Filed: September 11, 2017
    Publication date: January 11, 2018
    Inventors: Joseph Francis Krzyzaniak, George Michael Laurence, Aeri Park, Kevin Quackenbush, Marie Louise Reynolds, Peter Robert Rose, Timothy Andrew Woods
  • Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
    Patent number: 9790177
    Abstract: Novel forms of [R—(R*,R*)]-2-(4-fluorophenyl)-?,?-Dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Forms XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX characterized by their X-ray powder diffraction, solid state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: October 17, 2017
    Assignee: Warner-Lambert Company LLC
    Inventors: George Michael Laurence, Aeri Park, Timothy Andrew Woods
  • Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors
    Patent number: 9624218
    Abstract: Pyrido[2,3-d]pyrimidin-4-one compounds, formulations containing those compounds, and their use as tankyrase 1 and 2 inhibitors Formula (I).
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: April 18, 2017
    Assignee: Eli Lilly and Company
    Inventors: Marcio Chedid, Hisham Omer Eissa, Thomas Albert Engler, Kelly Wayne Furness, Kenneth B. Rank, Timothy Andrew Woods, Aaron D. Wrobleski
  • Novel Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta, Gamma-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)carbonyl]-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1)
    Publication number: 20170022156
    Abstract: Novel forms of [R, (R*,R*)]-2-(4-Fluorophenyl)-?,?dihydroxy-5-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Forms XXV, Form XXVII, Form XXVIII, Form XXXIX, and Forms XXX, characterized by their X-ray powder diffractor, solid state NMR, and/or Raman spectroscopy are describes as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer) disease.
    Type: Application
    Filed: October 4, 2016
    Publication date: January 26, 2017
    Inventors: Joseph Francis Krzyzaniak, George Michael Laurence, Aeri Park, Kevin Quackenbush, Marie Louise Reynolds, Peter Robert Rose, Timothy Andrew Woods
  • Selective BACE1 inhibitors
    Patent number: 9522923
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof, that are inhibitors of BACE.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: December 20, 2016
    Assignee: Eli Lilly and Company
    Inventors: Simon James Richards, Erik James Hembre, Jose Eduardo Lopez, Leonard Larry Winneroski, Jr., Timothy Andrew Woods, Jennifer Anne McMahon
  • 5'-SUBSTITUTED NUCLEOSIDE COMPOUNDS
    Publication number: 20160326208
    Abstract: The present invention relates to novel 5?-substituted nucleoside compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer, in particular glioblastomas, melanoma, sarcomas, gastric cancer, pancreatic cancer, cholangiocarcinoma, bladder cancer, breast cancer, non-small cell lung cancer, leukemias including acute myeloid leukemia, and lymphomas.
    Type: Application
    Filed: April 27, 2016
    Publication date: November 10, 2016
    Inventors: Guillermo S CORTEZ, Karl Robert DAHNKE, Michael John GROGAN, Antonio Rodriguez HERGUETA, James Andrew JAMISON, Brian Morgan WATSON, Timothy Andrew WOODS, Zahid Quyoom BONDAY
  • PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS
    Publication number: 20160251348
    Abstract: Pyrido[2,3-d]pyrimidin-4-one compounds, formulations containing those compounds, and their use as tankyrase 1 and 2 inhibitors Formula (I).
    Type: Application
    Filed: October 29, 2014
    Publication date: September 1, 2016
    Inventors: Marcio CHEDID, Hisham Omer EISSA, Thomas Albert ENGLER, Kelly Wayne FURNESS, Kenneth B. RANK, Timothy Andrew WOODS, Aaron D. WROBLESKI
  • SELECTIVE BACE1 INHIBITORS
    Publication number: 20160244465
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 17, 2016
    Publication date: August 25, 2016
    Inventors: Simon James Richards, Erik James Hembre, Jose Eduardo Lopez, Leonard Larry Winneroski, Jr., Timothy Andrew Woods, Jennifer Anne McMahon
  • Novel Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta, Gamma-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)carbonyl]-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1)
    Publication number: 20160046575
    Abstract: Novel forms of [R—(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX, characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.
    Type: Application
    Filed: October 27, 2015
    Publication date: February 18, 2016
    Inventors: Joseph Francis Krzyzaniak, George Michael Laurence, Aeri Park, Kevin Quackenbush, Marie Louise Reynolds, Peter Robert Rose, Timothy Andrew Woods
  • CDC7 inhibitors
    Patent number: 9156824
    Abstract: The present invention provides isoindolinone compounds, or a pharmaceutically acceptable salt thereof, that inhibit CDC7 and, therefore may be useful in treating cancer.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: October 13, 2015
    Assignee: Eli Lilly and Company
    Inventors: Robert Dean Dally, Timothy Andrew Woods
  • Novel Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta, Gamma-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)carbonyl]-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1)
    Publication number: 20150045563
    Abstract: Novel forms of [R—(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX, characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.
    Type: Application
    Filed: October 22, 2014
    Publication date: February 12, 2015
    Inventors: Joseph Francis Krzyzaniak, George Michael Laurence, Aeri Park, Kevin Quackenbush, Marie Louise Reynolds, Peter Robert Rose, Timothy Andrew Woods
  • CDC7 Inhibitors
    Publication number: 20140275121
    Abstract: The present invention provides isoindolinone compounds, or a pharmaceutically acceptable salt thereof, that inhibit CDC7 and, therefore may be useful in treating cancer.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 18, 2014
    Applicant: Eli Lilly and Company
    Inventors: Robert Dean DALLY, Timothy Andrew WOODS
  • Imidazole derivatives useful for the treatment of arthritis
    Patent number: 8648200
    Abstract: The present invention provides compounds of the formula below: where A, X and R1-R6 are as described herein, a pharmaceutical salt thereof, and a pharmaceutical composition containing this compound; methods of treating pain associated with osteoarthritis using one of the compounds or a pharmaceutically acceptable salt thereof, and processes for preparing the compounds.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: February 11, 2014
    Assignee: Eli Lilly and Company
    Inventors: Norman Earle Hughes, Bryan Hurst Norman, Timothy Andrew Woods
  • Novel Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta, Gamma-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)carbonyl]-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1)
    Publication number: 20140018546
    Abstract: Novel forms of [R—(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX, characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.
    Type: Application
    Filed: September 9, 2013
    Publication date: January 16, 2014
    Applicant: Warner-Lambert Company LLC
    Inventors: Joseph Francis Krzyzaniak, George Michael Laurence, Aeri Park, Kevin Quackenbush, Marie Louise Reynolds, Peter Robert Rose, Timothy Andrew Woods